July 24, 2007 - A new U.S. study published in the early online edition of Circulation, the journal of the American Heart Association, found that drinking more than one soft drink a day, whether regular or diet, may be linked to an increased risk of developing heart disease, due to an increase in metabolic syndrome.

July 24, 2007 – Biotonik announced that it has enrolled the first patient and largest trial, REPLACE Registry, which focuses on the complications associated with replacements and system upgrades of implantable pacemakers and defibrillators, and is designed to collect important data currently lacking, on risks associated with device generator replacements.

July 22, 2007 – ev3 Inc. and FoxHollow Technologies, Inc. announced a definitive agreement by which ev3 and FoxHollow will merge in a $780 million cash and stock transaction to create a new company with a market capitalization of approximately $1.7 billion to become a global leader in endovascular devices with net sales in 2008 projected to be in the range of $585 to $615 million.

July 23, 2007 - Teleflex Inc., a global supplier of disposable medical products used in critical care, specialty medical, and surgical applications and Arrow International Inc. announced today that they have entered into a definitive agreement pursuant to which Teleflex will acquire Arrow in an all cash transaction valued at approximately $2 billion.

July 20, 2007 – Despite forecasts by analysts at Thomson Financial that Boston Scientific Corp. would earn $150 million in the second quarter of this year, the company came up short at $115 million in the second quarter, or 7.7 cents a share, due to a significant sales slump in implantable defibrillators and coronary stents.
In 2006, Boston Scientific reported a $4.3 billion loss from its April 2006 purchase of Guidant Corp. Excluding special charges related to the acquisition, the company's profit fell 56 percent from the second quarter of 2006.

Source: Wall Street Journal Online

July 20, 2007 - U.S. doctors implanted fewer coronary stents in June than any other month in the last year, according to a market researcher, indicating that medical studies critical of the devices appear to be having a sustained impact.

July 20, 2007 – Oraganogenesis Inc. announced that it has received regulatory approval in Canada and Europe for BioSTAR, a device that incorporates a bioresorbable collagen scaffold used to treat patent foramen ovale (PFO), a hole in the heart that is usually asymptomatic.

July 19, 2007 – Abbott announced that the first patient was enrolled in its XIENCE V SPIRIT WOMEN clinical trial, the first clinical trial designed to study the safety and effectiveness of drug eluting stent treatment in women.

July 19, 2007 – AtCor Medical Holdings Ltd., the developer and marketer of the SphygmoCor system, which noninvasively measures central blood pressures, announced that it has signed an $1.8 million deal with three leading international pharmaceutical companies to supply SphygmoCor systems and clinical trial support services for new and ongoing drug trials in Europe and the United States.

July 18, 2007 - Abiomed Inc. announced that its Impella 2.5 and Impella 5.0 circulatory support technologies, new catheter-based circulatory support technology for heart failure patients, have been approved for use in Canada by Health Canada's Therapeutic Products Programme (TPP). In addition, the Company also announced that the first patients in Canada have received treatment with the Impella 2.5 technology at the Peter Munk Cardiac Centre at Toronto General Hospital.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now